Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study

다국어 초록 (Multilingual Abstract)

Purpose The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti–programmed cell death-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT.
Materials and Methods This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child-Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment-related adverse events were analyzed to assess safety profiles.
Results During a median follow-up of 11.23 months (range, 3.07 to 34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The 2-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively.
Conclusion Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.

참고문헌 (Reference)

• 1 Ding X, "Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus : a prospective randomized study" 127 : 3782-3793, 2021
• 2 Niu ZJ, "Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus : using a new classification" 29 : 2992-2997, 2012
• 3 Cai M, "Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma : a retrospective cohort study" 13 : 848387-, 2022
• 4 Finn RS, "Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease : a systematic review and meta-analysis" 67 : 422-435, 2018
• 5 Lee HS, "The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction : a prospective controlled study" 79 : 2087-2094, 1997
• 6 Yang B, "TACE plus lenvatinib versus TACE plus sorafenib for unresectable hepatocellular carcinoma with portal vein tumor thrombus : a prospective cohort study" 11 : 821599-, 2021
• 7 Rimassa L, "Systemic treatment options in hepatocellular carcinoma" 8 : 427-446, 2019
• 8 He M, "Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion : a randomized clinical trial" 5 : 953-960, 2019
• 9 Zheng K, "Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis : a randomized trial" 303 : 455-464, 2022
• 10 Yu JI, "Safety and efficacy of liver-directed radiotherapy in combination with lenvatinib for hepatocelluar carcinoma with macroscopic tumor thrombosis" 12 : 888755-, 2022
• 11 Kudo M, "Report of the 20th nationwide follow-up survey of primary liver cancer in Japan" 50 : 15-46, 2020
• 12 Yoon SM, "Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein : long-term patient outcomes" 82 : 2004-2011, 2012
• 13 Finn RS, "Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma" 38 : 2960-2970, 2020
• 14 Lin KY, "Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody : a retrospective multicenter study of 83 patients" 17 : 1477-1489, 2023
• 15 Galle PR, "Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma(IMbrave150) : an open-label, randomised, phase 3 trial" 22 : 991-1001, 2021
• 16 Kudo M, "Overall survival and objective response in advanced unresectable hepatocellular carcinoma : a subanalysis of the REFLECT study" 78 : 133-141, 2023
• 17 Wu JY, "Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial che-moembolization combined with lenvatinib plus anti-PD-1 antibodies : a multicenter retrospective study" 12 : 229-237, 2023
• 18 Llovet JM, "Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma(LEAP-002) : a randomised, double-blind, phase 3 trial" 24 : 1399-1410, 2023
• 19 Wu JY, "Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma : a multicenter retrospective study" 8 : 1233-1240, 2021
• 20 Ducreux M, "IMbrave150 : exploratory analysis to examine the association between treatment response and overall survival(OS)in patients(pts)with unresectable hepatocellular carcinoma(HCC)treated with atezolizumab(atezo)+ bevacizumab(bev)versus sorafenib(sor)" 39 (39): 4071-, 2021
• 21 Llovet JM, "Hepatocellular carcinoma" 7 : 6-, 2021
• 22 Yamada R, "Hepatic artery embolization in 120 patients with unresectable hepatoma" 148 : 397-401, 1983
• 23 Zhou J, "Guidelines for the diagnosis and treatment of hepatocellular carcinoma(2019 edition)" 9 : 682-720, 2020
• 24 Sun J, "Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2021 edition)" 11 : 315-328, 2022
• 25 Pan Y, "Factors influencing the prognosis patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma undergoing salvage surgery after conversion therapy" 12 : 1852-1862, 2023
• 26 Finn RS, "Evolution of systemic therapy for hepatocellular carcinoma" 73 (73): 150-157, 2021
• 27 Zou X, "Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus" 40 : 1686-1704, 2023
• 28 Feng JK, "Efficacy and safety of transarterial chemoembolization plus anti-angiogenic-targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world" 12 : 954203-, 2022
• 29 Li X, "Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China real-world" 12 : 950266-, 2022
• 30 Zhu XD, "Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations" 10 : 320-329, 2021
• 31 Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases" 68 : 723-750, 2018
• 32 Zou X, "Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features" 12 : 11315-11333, 2023
• 33 Lewis S, "Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC" 47 : 969-980, 2022
• 34 Cheng S, "Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus(2018 Edition)" 9 : 28-40, 2020
• 35 Xu J, "Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma(RESCUE) : a nonrandomized, open-label, phase II trial" 27 : 1003-1011, 2021
• 36 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma" 13 : 227-299, 2019